Home

CARGO Therapeutics, Inc. - Common Stock (CRGX)

4.1550
+0.3550 (9.34%)

CARGO Therapeutics, Inc. is a biotechnology company focused on the development of innovative therapies for treating cancer and other serious diseases

The company specializes in harnessing and engineering cellular therapies, particularly in the field of immuno-oncology, to create targeted treatment options that aim to enhance the body’s natural ability to fight cancer. By leveraging advanced technologies and a deep understanding of the immune system, CARGO Therapeutics is committed to advancing groundbreaking treatments that can improve patient outcomes and provide new hope for those affected by difficult-to-treat conditions.

SummaryNewsPress ReleasesChartHistoricalFAQ
Previous Close3.800
Open4.500
Bid4.150
Ask4.160
Day's Range4.040 - 4.550
52 Week Range3.000 - 32.79
Volume3,483,971
Market Cap-
PE Ratio (TTM)-
EPS (TTM)-
Dividend & YieldN/A (N/A)
1 Month Average Volume591,644

News & Press Releases

Discover the top movers in Wednesday's pre-market session.chartmill.com
Wondering what's happening in Wednesday's pre-market session? Find an overview in this article.
Via Chartmill · March 19, 2025
12 Health Care Stocks Moving In Wednesday's Pre-Market Sessionbenzinga.com
Via Benzinga · March 19, 2025
Why StoneCo Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · March 19, 2025
Which stocks are moving after the closing bell on Tuesday?chartmill.com
Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.
Via Chartmill · March 18, 2025
12 Health Care Stocks Moving In Tuesday's After-Market Sessionbenzinga.com
Via Benzinga · March 18, 2025
CARGO Therapeutics Provides Corporate Update
- Development of CRG-023 and allogeneic platform suspended; further reduction in force (RIF) of approximately 90% to preserve cash and maximize shareholder value -
By Cargo Therapeutics, Inc. · Via GlobeNewswire · March 18, 2025
Retail Traders Flocked To These 5 Biotech Stocks In January — Here’s Whystocktwits.com
Biotech remains a high-risk, high-reward sector, and this month’s top draws reflect retail’s appetite for stocks with major clinical and regulatory catalysts.
Via Stocktwits · January 31, 2025
On Friday, there are stocks with unusual volume. Let's take a look.chartmill.com
Unusual volume stocks are being observed in Friday's session.
Via Chartmill · January 31, 2025
Let's take a look at the stocks that are in motion in today's session.chartmill.com
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.
Via Chartmill · January 30, 2025
Top stock movements in today's session.chartmill.com
Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.
Via Chartmill · January 30, 2025
There are notable gap-ups and gap-downs in today's session.chartmill.com
Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
Via Chartmill · January 30, 2025
Stay updated with the stocks that are on the move in today's pre-market session.chartmill.com
Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top gainers and losers in today's pre-market session.
Via Chartmill · January 30, 2025
Nasdaq Moves Lower; Meta Platforms Posts Strong Salesbenzinga.com
Via Benzinga · January 30, 2025
Dow Jumps Over 100 Points; Tesla Earnings Miss Viewsbenzinga.com
Via Benzinga · January 30, 2025
This Everest Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursdaybenzinga.com
Via Benzinga · January 30, 2025
12 Health Care Stocks Moving In Thursday's Pre-Market Sessionbenzinga.com
Via Benzinga · January 30, 2025
Curious about the stocks that are showing activity after the closing bell on Wednesday?chartmill.com
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
Via Chartmill · January 29, 2025
Why Meta Platforms Shares Are Trading Higher; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · January 30, 2025
CARGO Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - CRGX
The DJS Law Group announces that it is investigating claims on behalf of investors of CARGO Therapeutics, Inc. (“CARGO” or “the Company”) (NASDAQ: CRGX) for violations of the securities laws.
By DJS Law Group · Via Business Wire · January 29, 2025
CRGX Investors Have Opportunity to Join CARGO Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CARGO Therapeutics, Inc. (“CARGO” or “the Company”) (NASDAQ: CRGX) for violations of the securities laws.
By The Schall Law Firm · Via Business Wire · January 29, 2025
CARGO Therapeutics to Discontinue FIRCE-1 Phase 2 Study of Firi-cel; Advances Remaining Programs While Evaluating Strategic Options
SAN CARLOS, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company advancing next generation, potentially curative cell therapies for cancer patients, today announced that it has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy. In-line with this decision, the Company will reduce its workforce to extend cash runway and prioritize the advancement of CRG-023 to Phase 1 proof-of-concept data as well as its novel allogeneic platform.
By Cargo Therapeutics, Inc. · Via GlobeNewswire · January 29, 2025
CARGO Therapeutics Provides Corporate Update and Anticipated Milestones for 2025
- 71 patients dosed in the potentially pivotal Phase 2 clinical study of firicabtagene autoleucel (firi-cel); Interim analysis results expected to be reported in 1H’25 -
By Cargo Therapeutics, Inc. · Via GlobeNewswire · January 10, 2025
Axsome Therapeutics, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Sessionbenzinga.com
Via Benzinga · December 30, 2024
CARGO Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
SAN CARLOS, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next-generation, potentially curative cell therapies for cancer patients, today announced that the company will participate in the 43rd Annual J.P. Morgan Healthcare Conference, taking place January 13-16, 2025, in San Francisco, California.
By Cargo Therapeutics, Inc. · Via GlobeNewswire · December 17, 2024
CARGO Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
- 57 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel (firi-cel); on track for interim analysis in 1H25 -
By Cargo Therapeutics, Inc. · Via GlobeNewswire · November 12, 2024